Probiotics for Recurrent Urinary Tract Infection Prevention in Women: Evidence‑Based Recommendations

Guideline Recommendations

The Society of Obstetricians and Gynaecologists of Canada (2010) explicitly states that probiotics and vaccines are not recommended for the prevention of recurrent urinary tract infections in women. Guideline recommendation (no specific strength indicated). [@2]
The Society of Obstetricians and Gynaecologists of Canada permits the use of intravaginal probiotics containing Lactobacillus rhamnosus GR‑1 or Lactobacillus reuteri RC‑14 once or twice weekly as an adjunctive prophylactic measure. Guideline recommendation (evidence classified as critically low). [@2]

A high‑quality systematic review (AMSTAR 2 rating: High) of 6 randomized controlled trials (352 participants) found no significant reduction in recurrent UTI rates with probiotics versus placebo (Risk Ratio 0.82, 95 % CI 0.60–1.12). Evidence quality: High. [@1]
Meta‑analyses published between 2012 and 2015, encompassing premenopausal adult women, demonstrated no statistically significant benefit of Lactobacillus probiotics compared with control (RR 0.85, 95 % CI 0.58–1.25). Evidence quality: Critically low. [@8]
The same meta‑analyses reported critically low overall evidence quality, citing substantial heterogeneity in probiotic strains, formulations, dosing regimens, and follow‑up periods. Evidence quality: Critically low. [@8]
The largest meta‑analysis included 294 patients across 5 studies, highlighting small sample sizes and lack of standardisation across trials. Evidence quality: Critically low. [@7]

Critically low‑quality evidence indicates that vaginal suppositories containing Lactobacillus crispatus CTV‑05 or the combination of Lactobacillus rhamnosus GR‑1 + Lactobacillus fermentum B‑54 (now classified as L. reuteri RC‑14) were the most effective among the strains studied. Evidence quality: Critically low. [@7]

Oral probiotics have not shown benefit; positive signals are limited to vaginal administration of the specific strains noted above. Evidence quality: Critically low. [@7]
Probiotics should not be used as monotherapy; they may be considered only as an adjunct after first‑line interventions have been attempted. Guideline recommendation (no strength specified). [@2]
Treating asymptomatic bacteriuria is discouraged because it promotes antimicrobial resistance and increases recurrence risk. Evidence quality: Critically low. [@6]
Lactobacillus probiotics are generally safe, with minimal adverse effects reported in the available studies. Evidence quality: Critically low. [@7]